PTNT

Prothrombin G20210A Mutation, Blood

Patient ID	Patient Name		Birth Date	Gender	Age
SA00145546	TESTINGRNV, REPORT		1999-09-09	M	21
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00145546	SA00145546	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		20 Jul 2021 07:00			

Prothrombin G20210A Mutation, B

PTNT Interpretation

[1] MCR

This individual DOES have the Prothrombin F2 c.*97G>A, (legacy numbering G20210A) variant on ONE allele, (heterozygous carrier). The Prothrombin (F2 c.*97G>A) variant is a mild risk factor for venous thromboembolism (VTE). This individual may have other genetic and environmental risk factors for VTE. If indicated, consider genetic consultation and counseling for this individual and potentially affected family members regarding laboratory testing.

ADDITIONAL INFORMATION

This test uses TaqMan Genotyping chemistry to amplify and detect specific single nucleotide polymorphisms in purified genomic DNA.

DISCLAIMER

Patients receiving allogenic stem cell transplants prior to having blood drawn for DNA based testing may have false normal or abnormal results depending on the genotype of the stem cell donor.

Prothrombin G20210A Mutation, B

MCR

	Reference Value
Heterozygous Abn	Negative

PTNT Reviewed By

MCR

BENJAMIN BAILEY

Received: 21 Jul 2021 15:42 **Reported:** 21 Jul 2021 15:50

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292